Intralesional Therapy for Melanoma Effective, May Have Systemic Activity

Source: Med Page Today, June 2024

CHICAGO — Preoperative intralesional treatment with a dual antibody-cytokine fusion significantly improved relapse-free survival (RFS) in locally advanced melanoma versus surgery alone, a randomized trial showed.

Median RFS more than doubled when patients received daromun before surgery (16.7 vs 6.8 months). Landmark analyses showed similar advantages in favor of daromun out to 3 years. Results were similar for blinded review and investigator assessment.

The intralesional therapy also significantly improved distant metastasis-free survival (DMFS), suggesting the local therapy induced a systemic immune response, reported Axel Hauschild, MD, of University Hospital Schleswig-Holstein in Kiel, Germany, at the American Society of Clinical Oncology
READ THE ORIGINAL FULL ARTICLE